
Community Acquired Pneumonia Market
Description
Community Acquired Pneumonia Market Report and Forecast 2024-2032
The community acquired pneumonia market was valued at USD 1586.2 million driven by the increasing demand for effective treatments, particularly in response to the rising incidence of the condition, especially among elderly and immunocompromised individuals. The market is projected to grow at a CAGR of 7.7% during the forecast period of 2024-2032, and likely to achieve a market value of 3092.4 million by 2032.
Community Acquired Pneumonia Market Analysis
Community acquired pneumonia is a lung infection contracted outside hospital settings, typically caused by bacteria, viruses, or fungi. It can affect individuals of all ages, but the elderly, infants, and immunocompromised individuals are most vulnerable. Treatment involves antibiotics, antivirals, or antifungals, depending on the cause. Community-acquired pneumonia remains a leading cause of morbidity and mortality worldwide, driving the demand for effective treatment options and preventive measures. Increased awareness improved diagnostic tools, and the availability of advanced therapies are boosting the market for community-acquired pneumonia treatments.
Market Drivers
Rising Incidence of Community-Acquired Pneumonia: The increasing prevalence of community-acquired pneumonia, especially among elderly populations and immunocompromised individuals, is a major driver for the market. As the population ages and risk factors like chronic respiratory diseases and smoking remain prevalent, the demand for effective community-acquired pneumonia treatments continues to grow.
Advancements in Antibiotic Development: New antibiotics, particularly pleuromutilin and cephalosporin classes, are being developed to combat drug-resistant bacteria. These advancements are crucial in treating severe cases of community-acquired pneumonia, where traditional antibiotics are no longer effective. The introduction of more potent antibiotics is expected to fuel the market’s expansion.
Increasing Healthcare Expenditure: With rising healthcare expenditure, particularly in developing regions, more resources are being allocated to the diagnosis and treatment of infectious diseases such as community-acquired pneumonia. Governments and healthcare organisations are investing in better healthcare infrastructure and treatment options, further driving the market growth.
Rising Vaccination Rates: Vaccination programmes, particularly for pneumococcal bacteria, a common cause of community-acquired pneumonia, are reducing the incidence of pneumonia. However, vaccine effectiveness declines with age, and many people are still vulnerable, maintaining a steady demand for treatment options. The emphasis on preventive care is indirectly boosting the market for community-acquired pneumonia therapies.
Favourable Reimbursement Policies: Favourable reimbursement policies for pneumonia treatments in many countries are encouraging patients to seek timely medical intervention. As community-acquired pneumonia treatment often requires hospitalisation or prolonged antibiotic therapy, these policies ensure that more patients can afford necessary care, contributing to the market's growth.
Challenges
Rising Antibiotic Resistance: One of the key challenges facing the community-acquired pneumonia market is the growing resistance to antibiotics. The widespread misuse and overuse of antibiotics have resulted in multi-drug resistant bacterial strains, complicating treatment efforts and reducing the effectiveness of traditional therapies.
High Treatment Costs: The treatment of community-acquired pneumonia, particularly in severe cases requiring hospitalisation and advanced antibiotic therapies, can be expensive. High costs, especially in regions with limited healthcare coverage, present a challenge for patients and healthcare systems, limiting access to effective treatments.
Delayed Diagnosis: Delayed or inaccurate diagnosis of community-acquired pneumonia can lead to inappropriate treatment, which exacerbates the disease and increases mortality rates. In many low-resource settings, the lack of advanced diagnostic tools remains a significant hurdle to timely and accurate community-acquired pneumonia treatment.
Adverse Effects of Long-Term Antibiotic Use: The long-term use of antibiotics to treat severe community-acquired pneumonia cases can lead to adverse effects, including gastrointestinal issues and an increased risk of secondary infections. These side effects can deter patients from adhering to prescribed treatments, reducing the overall effectiveness of antibiotic therapies.
Lack of Awareness in Developing Regions: In many developing regions, awareness about community-acquired pneumonia symptoms and the importance of early treatment is limited. This results in delayed care, worsening outcomes, and a higher burden on healthcare systems. Increasing public awareness and education is necessary to address this challenge effectively.
Future Opportunities
Development of Novel Antibiotics: There is a growing opportunity in the development of novel antibiotics to combat drug-resistant strains of bacteria responsible for community-acquired pneumonia. As antibiotic resistance continues to rise, pharmaceutical companies are focusing on creating more effective treatments that can bypass current resistance mechanisms.
Focus on Point-of-Care Diagnostics: Point-of-care diagnostic tools for community-acquired pneumonia are becoming more prevalent, allowing for faster and more accurate diagnosis in clinical settings. These tools help healthcare providers determine the most appropriate treatment options, improving outcomes and reducing unnecessary antibiotic use, thereby providing a growth opportunity in the market.
Increasing Demand for Vaccines: The demand for pneumococcal vaccines and other vaccines that prevent respiratory infections is on the rise. As governments and health organisations promote vaccination programs, there is an opportunity to reduce the incidence of community-acquired pneumonia, which could drive demand for preventive care solutions.
Telemedicine and Remote Monitoring: The increasing adoption of telemedicine for remote monitoring of respiratory infections offers an opportunity to manage community-acquired pneumonia more efficiently. Patients in remote areas can receive timely consultations and treatment recommendations, improving care access and adherence to prescribed therapies.
Community Acquired Pneumonia Market Trends
The industry is evolving rapidly, driven by technological innovations and advancements in various practices. As continuous research uncovers new insights across sectors, several key trends are emerging, shaping the future direction of the market. These trends are expected to significantly influence the landscape, improving outcomes, enhancing precision, and expanding access to advanced solutions across products, therapies, and services.
Community Acquired Pneumonia Market Segmentation
Market Breakup by Type
Market Breakup by Drug Class
Market Breakup by Dosage Form
Market Breakup by Route of Administration
Market Breakup by End User
Market Breakup by Distribution Channel
Market Breakup by Region
Community Acquired Pneumonia Market Competitive Landscape
Key players in the community-acquired pneumonia market include Pfizer, AstraZeneca, Novartis AG, Mylan N.V., Sanofi SA, Takeda Pharmaceutical Company Limited, Sun Pharmaceuticals Inc., AbbVie Inc., and GSK plc. These companies are focusing on developing advanced antibiotics, vaccines, and combination therapies to manage community-acquired pneumonia. Strategic collaborations, clinical trials, and product launches are key strategies employed by these companies to maintain their market position and drive growth.
Key Questions Answered in the Report
What are the key factors driving the growth of the community acquired pneumonia market?
How is antibiotic resistance impacting the treatment of community acquired pneumonia?
What advancements in diagnostic imaging are improving community acquired pneumonia diagnosis?
How is the use of combination therapies changing community acquired pneumonia treatment strategies?
Which regions are expected to see the highest demand for community acquired pneumonia treatments in the coming years?
How are telemedicine platforms improving access to care for community acquired pneumonia patients?
What role does vaccination play in preventing community acquired pneumonia?
How are outpatient treatment models influencing community acquired pneumonia management?
What new antibiotics are in development to combat drug-resistant strains of bacteria causing community acquired pneumonia?
How are pharmaceutical companies addressing the challenges of delayed diagnosis in community acquired pneumonia?
How do reimbursement policies vary across regions for community acquired pneumonia treatment?
Key Benefits for Stakeholders
The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the community acquired pneumonia market from 2017-2032.
The research report provides the latest information on the market drivers, challenges, and opportunities in the community acquired pneumonia market.
The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders analyze the level of competition within the community acquired pneumonia industry and its attractiveness.
The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
The community acquired pneumonia market was valued at USD 1586.2 million driven by the increasing demand for effective treatments, particularly in response to the rising incidence of the condition, especially among elderly and immunocompromised individuals. The market is projected to grow at a CAGR of 7.7% during the forecast period of 2024-2032, and likely to achieve a market value of 3092.4 million by 2032.
Community Acquired Pneumonia Market Analysis
Community acquired pneumonia is a lung infection contracted outside hospital settings, typically caused by bacteria, viruses, or fungi. It can affect individuals of all ages, but the elderly, infants, and immunocompromised individuals are most vulnerable. Treatment involves antibiotics, antivirals, or antifungals, depending on the cause. Community-acquired pneumonia remains a leading cause of morbidity and mortality worldwide, driving the demand for effective treatment options and preventive measures. Increased awareness improved diagnostic tools, and the availability of advanced therapies are boosting the market for community-acquired pneumonia treatments.
Market Drivers
Rising Incidence of Community-Acquired Pneumonia: The increasing prevalence of community-acquired pneumonia, especially among elderly populations and immunocompromised individuals, is a major driver for the market. As the population ages and risk factors like chronic respiratory diseases and smoking remain prevalent, the demand for effective community-acquired pneumonia treatments continues to grow.
Advancements in Antibiotic Development: New antibiotics, particularly pleuromutilin and cephalosporin classes, are being developed to combat drug-resistant bacteria. These advancements are crucial in treating severe cases of community-acquired pneumonia, where traditional antibiotics are no longer effective. The introduction of more potent antibiotics is expected to fuel the market’s expansion.
Increasing Healthcare Expenditure: With rising healthcare expenditure, particularly in developing regions, more resources are being allocated to the diagnosis and treatment of infectious diseases such as community-acquired pneumonia. Governments and healthcare organisations are investing in better healthcare infrastructure and treatment options, further driving the market growth.
Rising Vaccination Rates: Vaccination programmes, particularly for pneumococcal bacteria, a common cause of community-acquired pneumonia, are reducing the incidence of pneumonia. However, vaccine effectiveness declines with age, and many people are still vulnerable, maintaining a steady demand for treatment options. The emphasis on preventive care is indirectly boosting the market for community-acquired pneumonia therapies.
Favourable Reimbursement Policies: Favourable reimbursement policies for pneumonia treatments in many countries are encouraging patients to seek timely medical intervention. As community-acquired pneumonia treatment often requires hospitalisation or prolonged antibiotic therapy, these policies ensure that more patients can afford necessary care, contributing to the market's growth.
Challenges
Rising Antibiotic Resistance: One of the key challenges facing the community-acquired pneumonia market is the growing resistance to antibiotics. The widespread misuse and overuse of antibiotics have resulted in multi-drug resistant bacterial strains, complicating treatment efforts and reducing the effectiveness of traditional therapies.
High Treatment Costs: The treatment of community-acquired pneumonia, particularly in severe cases requiring hospitalisation and advanced antibiotic therapies, can be expensive. High costs, especially in regions with limited healthcare coverage, present a challenge for patients and healthcare systems, limiting access to effective treatments.
Delayed Diagnosis: Delayed or inaccurate diagnosis of community-acquired pneumonia can lead to inappropriate treatment, which exacerbates the disease and increases mortality rates. In many low-resource settings, the lack of advanced diagnostic tools remains a significant hurdle to timely and accurate community-acquired pneumonia treatment.
Adverse Effects of Long-Term Antibiotic Use: The long-term use of antibiotics to treat severe community-acquired pneumonia cases can lead to adverse effects, including gastrointestinal issues and an increased risk of secondary infections. These side effects can deter patients from adhering to prescribed treatments, reducing the overall effectiveness of antibiotic therapies.
Lack of Awareness in Developing Regions: In many developing regions, awareness about community-acquired pneumonia symptoms and the importance of early treatment is limited. This results in delayed care, worsening outcomes, and a higher burden on healthcare systems. Increasing public awareness and education is necessary to address this challenge effectively.
Future Opportunities
Development of Novel Antibiotics: There is a growing opportunity in the development of novel antibiotics to combat drug-resistant strains of bacteria responsible for community-acquired pneumonia. As antibiotic resistance continues to rise, pharmaceutical companies are focusing on creating more effective treatments that can bypass current resistance mechanisms.
Focus on Point-of-Care Diagnostics: Point-of-care diagnostic tools for community-acquired pneumonia are becoming more prevalent, allowing for faster and more accurate diagnosis in clinical settings. These tools help healthcare providers determine the most appropriate treatment options, improving outcomes and reducing unnecessary antibiotic use, thereby providing a growth opportunity in the market.
Increasing Demand for Vaccines: The demand for pneumococcal vaccines and other vaccines that prevent respiratory infections is on the rise. As governments and health organisations promote vaccination programs, there is an opportunity to reduce the incidence of community-acquired pneumonia, which could drive demand for preventive care solutions.
Telemedicine and Remote Monitoring: The increasing adoption of telemedicine for remote monitoring of respiratory infections offers an opportunity to manage community-acquired pneumonia more efficiently. Patients in remote areas can receive timely consultations and treatment recommendations, improving care access and adherence to prescribed therapies.
Community Acquired Pneumonia Market Trends
The industry is evolving rapidly, driven by technological innovations and advancements in various practices. As continuous research uncovers new insights across sectors, several key trends are emerging, shaping the future direction of the market. These trends are expected to significantly influence the landscape, improving outcomes, enhancing precision, and expanding access to advanced solutions across products, therapies, and services.
- Growing Focus on Combination Therapies
- Advancements in Diagnostic Imaging
- Rising Adoption of Prophylactic Vaccination
- Integration of AI in Diagnostic Processes
- Increased Use of Outpatient Treatment Models
- Expansion of Clinical Trials for New Antibiotics
Community Acquired Pneumonia Market Segmentation
Market Breakup by Type
- Bacteria
- Virus
- Fungi
Market Breakup by Drug Class
- Pleuromutilin Antibiotic
- Cephalosporin
- Glycylcycline
- Oxazolidinone
- Ketolide
- Others
Market Breakup by Dosage Form
- Tablet
- Solution
- Others
Market Breakup by Route of Administration
- Oral
- Parenteral
Market Breakup by End User
- Hospitals and Clinics
- Ambulatory Surgical Centers
- Homecare Settings
- Others
Market Breakup by Distribution Channel
- Hospitals Pharmacies
- Independent Pharmacies
- Online Pharmacies
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Community Acquired Pneumonia Market Competitive Landscape
Key players in the community-acquired pneumonia market include Pfizer, AstraZeneca, Novartis AG, Mylan N.V., Sanofi SA, Takeda Pharmaceutical Company Limited, Sun Pharmaceuticals Inc., AbbVie Inc., and GSK plc. These companies are focusing on developing advanced antibiotics, vaccines, and combination therapies to manage community-acquired pneumonia. Strategic collaborations, clinical trials, and product launches are key strategies employed by these companies to maintain their market position and drive growth.
Key Questions Answered in the Report
What are the key factors driving the growth of the community acquired pneumonia market?
How is antibiotic resistance impacting the treatment of community acquired pneumonia?
What advancements in diagnostic imaging are improving community acquired pneumonia diagnosis?
How is the use of combination therapies changing community acquired pneumonia treatment strategies?
Which regions are expected to see the highest demand for community acquired pneumonia treatments in the coming years?
How are telemedicine platforms improving access to care for community acquired pneumonia patients?
What role does vaccination play in preventing community acquired pneumonia?
How are outpatient treatment models influencing community acquired pneumonia management?
What new antibiotics are in development to combat drug-resistant strains of bacteria causing community acquired pneumonia?
How are pharmaceutical companies addressing the challenges of delayed diagnosis in community acquired pneumonia?
How do reimbursement policies vary across regions for community acquired pneumonia treatment?
Key Benefits for Stakeholders
The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the community acquired pneumonia market from 2017-2032.
The research report provides the latest information on the market drivers, challenges, and opportunities in the community acquired pneumonia market.
The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders analyze the level of competition within the community acquired pneumonia industry and its attractiveness.
The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
Table of Contents
250 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Community Acquired Pneumonia Market Overview – 8 Major Markets
- 3.1 Community Acquired Pneumonia Market Historical Value (2018-2024)
- 3.2 Community Acquired Pneumonia Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Community Acquired Pneumonia Market Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Community Acquired Pneumonia Market - Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.1.1 Prevalence, by Country
- 7.1.1.1 United States
- 7.1.1.2 United Kingdom
- 7.1.1.3 Germany
- 7.1.1.4 France
- 7.1.1.5 Italy
- 7.1.1.6 Spain
- 7.1.1.7 Japan
- 7.1.1.8 India
- 7.1.2 Diagnosed Cases, by Country
- 7.1.2.1 United States
- 7.1.2.2 United Kingdom
- 7.1.2.3 Germany
- 7.1.2.4 France
- 7.1.2.5 Italy
- 7.1.2.6 Spain
- 7.1.2.7 Japan
- 7.1.2.8 India
- 7.1.3 Treatment Seeking Rate, by Country
- 7.1.3.1 United States
- 7.1.3.2 United Kingdom
- 7.1.3.3 Germany
- 7.1.3.4 France
- 7.1.3.5 Italy
- 7.1.3.6 Spain
- 7.1.3.7 Japan
- 7.1.3.8 India
- 8 Community Acquired Pneumonia Market Landscape – 8 Major Markets
- 8.1 Community Acquired Pneumonia Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Community Acquired Pneumonia Market: Product Landscape
- 8.2.1 Analysis by Type
- 8.2.2 Analysis by Drug Class
- 8.2.3 Analysis by Dosage Form
- 8.2.4 Analysis by Route of Administration
- 9 Community Acquired Pneumonia Market Challenges and Unmet Needs
- 9.1 Treatment Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 Community Acquired Pneumonia Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Community Acquired Pneumonia Market Segmentation (2018-2034) - 8 Major Markets
- 12.1 Community Acquired Pneumonia Market (2018-2034) by Type
- 12.1.1 Market Overview
- 12.1.2 Bacteria
- 12.1.3 Virus
- 12.1.4 Fungi
- 12.2 Community Acquired Pneumonia Market (2018-2034) by Drug Class
- 12.2.1 Market Overview
- 12.2.2 Pleuromutilin Antibiotic
- 12.2.3 Cephalosporin
- 12.2.4 Glycylcycline
- 12.2.5 Oxazolidinone
- 12.2.6 Ketolide
- 12.2.7 Others
- 12.3 Community Acquired Pneumonia Market (2018-2034) by Dosage Form
- 12.3.1 Market Overview
- 12.3.2 Tablet
- 12.3.3 Solution
- 12.3.4 Others
- 12.4 Community Acquired Pneumonia Market (2018-2034) by Route of Administration
- 12.4.1 Market Overview
- 12.4.2 Oral
- 12.4.3 Parenteral
- 12.5 Community Acquired Pneumonia Market (2018-2034) by End User
- 12.5.1 Market Overview
- 12.5.2 Hospitals & Clinics
- 12.5.3 Ambulatory Surgical Centers
- 12.5.4 Homecare Settings
- 12.5.5 Others
- 12.6 Community Acquired Pneumonia Market (2018-2034) by Distribution Channel
- 12.6.1 Market Overview
- 12.6.2 Hospitals Pharmacies
- 12.6.3 Independent Pharmacies
- 12.6.4 Online Pharmacies
- 12.6.5 Others
- 12.7 Community Acquired Pneumonia Market (2018-2034) by Country
- 12.7.1 Market Overview
- 12.7.2 United States
- 12.7.3 United Kingdom
- 12.7.4 Germany
- 12.7.5 France
- 12.7.6 Italy
- 12.7.7 Spain
- 12.7.8 Japan
- 12.7.9 India
- 13 United States Community Acquired Pneumonia Market (2018-2034)
- 13.1 United States Community Acquired Pneumonia Market Historical Value (2018-2024)
- 13.2 United States Community Acquired Pneumonia Market Forecast Value (2025-2034)
- 13.3 United States Community Acquired Pneumonia Market (2018-2034) by Type
- 13.3.1 Market Overview
- 13.3.2 Bacteria
- 13.3.3 Virus
- 13.3.4 Fungi
- 13.4 United States Community Acquired Pneumonia Market (2018-2034) by Drug Class
- 13.4.1 Market Overview
- 13.4.2 Pleuromutilin Antibiotic
- 13.4.3 Cephalosporin
- 13.4.4 Glycylcycline
- 13.4.5 Oxazolidinone
- 13.4.6 Ketolide
- 13.4.7 Others
- 13.5 United States Community Acquired Pneumonia Market (2018-2034) by Dosage Form
- 13.5.1 Market Overview
- 13.5.2 Tablet
- 13.5.3 Solution
- 13.5.4 Others
- 13.6 United States Community Acquired Pneumonia Market (2018-2034) by Route of Administration
- 13.6.1 Market Overview
- 13.6.2 Oral
- 13.6.3 Parenteral
- 13.7 United States Community Acquired Pneumonia Market (2018-2034) by End User
- 13.7.1 Market Overview
- 13.7.2 Hospitals & Clinics
- 13.7.3 Ambulatory Surgical Centers
- 13.7.4 Homecare Settings
- 13.7.5 Others
- 13.8 United States Community Acquired Pneumonia Market (2018-2034) by Distribution Channel
- 13.8.1 Market Overview
- 13.8.2 Hospitals Pharmacies
- 13.8.3 Independent Pharmacies
- 13.8.4 Online Pharmacies
- 13.8.5 Others
- 14 United Kingdom Community Acquired Pneumonia Market (2018-2034)
- 14.1 United Kingdom Community Acquired Pneumonia Market Historical Value (2018-2024)
- 14.2 United Kingdom Community Acquired Pneumonia Market Forecast Value (2025-2034)
- 14.3 United Kingdom Community Acquired Pneumonia Market (2018-2034) by Type
- 14.3.1 Market Overview
- 14.3.2 Bacteria
- 14.3.3 Virus
- 14.3.4 Fungi
- 14.4 United Kingdom Community Acquired Pneumonia Market (2018-2034) by Drug Class
- 14.4.1 Market Overview
- 14.4.2 Pleuromutilin Antibiotic
- 14.4.3 Cephalosporin
- 14.4.4 Glycylcycline
- 14.4.5 Oxazolidinone
- 14.4.6 Ketolide
- 14.4.7 Others
- 14.5 United Kingdom Community Acquired Pneumonia Market (2018-2034) by Dosage Form
- 14.5.1 Market Overview
- 14.5.2 Tablet
- 14.5.3 Solution
- 14.5.4 Others
- 14.6 United Kingdom Community Acquired Pneumonia Market (2018-2034) by Route of Administration
- 14.6.1 Market Overview
- 14.6.2 Oral
- 14.6.3 Parenteral
- 14.7 United Kingdom Community Acquired Pneumonia Market (2018-2034) by End User
- 14.7.1 Market Overview
- 14.7.2 Hospitals & Clinics
- 14.7.3 Ambulatory Surgical Centers
- 14.7.4 Homecare Settings
- 14.7.5 Others
- 14.8 United Kingdom Community Acquired Pneumonia Market (2018-2034) by Distribution Channel
- 14.8.1 Market Overview
- 14.8.2 Hospitals Pharmacies
- 14.8.3 Independent Pharmacies
- 14.8.4 Online Pharmacies
- 14.8.5 Others
- 15 Germany Community Acquired Pneumonia Market (2018-2034)
- 15.1 Germany Community Acquired Pneumonia Market Historical Value (2018-2024)
- 15.2 Germany Community Acquired Pneumonia Market Forecast Value (2025-2034)
- 15.3 Germany Community Acquired Pneumonia Market (2018-2034) by Type
- 15.3.1 Market Overview
- 15.3.2 Bacteria
- 15.3.3 Virus
- 15.3.4 Fungi
- 15.4 Germany Community Acquired Pneumonia Market (2018-2034) by Drug Class
- 15.4.1 Market Overview
- 15.4.2 Pleuromutilin Antibiotic
- 15.4.3 Cephalosporin
- 15.4.4 Glycylcycline
- 15.4.5 Oxazolidinone
- 15.4.6 Ketolide
- 15.4.7 Others
- 15.5 Germany Community Acquired Pneumonia Market (2018-2034) by Dosage Form
- 15.5.1 Market Overview
- 15.5.2 Tablet
- 15.5.3 Solution
- 15.5.4 Others
- 15.6 Germany Community Acquired Pneumonia Market (2018-2034) by Route of Administration
- 15.6.1 Market Overview
- 15.6.2 Oral
- 15.6.3 Parenteral
- 15.7 Germany Community Acquired Pneumonia Market (2018-2034) by End User
- 15.7.1 Market Overview
- 15.7.2 Hospitals & Clinics
- 15.7.3 Ambulatory Surgical Centers
- 15.7.4 Homecare Settings
- 15.7.5 Others
- 15.8 Germany Community Acquired Pneumonia Market (2018-2034) by Distribution Channel
- 15.8.1 Market Overview
- 15.8.2 Hospitals Pharmacies
- 15.8.3 Independent Pharmacies
- 15.8.4 Online Pharmacies
- 15.8.5 Others
- 16 France Community Acquired Pneumonia Market (2018-2034)
- 16.1 France Community Acquired Pneumonia Market Historical Value (2018-2024)
- 16.2 France Community Acquired Pneumonia Market Forecast Value (2025-2034)
- 16.3 France Community Acquired Pneumonia Market (2018-2034) by Type
- 16.3.1 Market Overview
- 16.3.2 Bacteria
- 16.3.3 Virus
- 16.3.4 Fungi
- 16.4 France Community Acquired Pneumonia Market (2018-2034) by Drug Class
- 16.4.1 Market Overview
- 16.4.2 Pleuromutilin Antibiotic
- 16.4.3 Cephalosporin
- 16.4.4 Glycylcycline
- 16.4.5 Oxazolidinone
- 16.4.6 Ketolide
- 16.4.7 Others
- 16.5 France Community Acquired Pneumonia Market (2018-2034) by Dosage Form
- 16.5.1 Market Overview
- 16.5.2 Tablet
- 16.5.3 Solution
- 16.5.4 Others
- 16.6 France Community Acquired Pneumonia Market (2018-2034) by Route of Administration
- 16.6.1 Market Overview
- 16.6.2 Oral
- 16.6.3 Parenteral
- 16.7 France Community Acquired Pneumonia Market (2018-2034) by End User
- 16.7.1 Market Overview
- 16.7.2 Hospitals & Clinics
- 16.7.3 Ambulatory Surgical Centers
- 16.7.4 Homecare Settings
- 16.7.5 Others
- 16.8 France Community Acquired Pneumonia Market (2018-2034) by Distribution Channel
- 16.8.1 Market Overview
- 16.8.2 Hospitals Pharmacies
- 16.8.3 Independent Pharmacies
- 16.8.4 Online Pharmacies
- 16.8.5 Others
- 17 Italy Community Acquired Pneumonia Market (2018-2034)
- 17.1 Italy Community Acquired Pneumonia Market Historical Value (2018-2024)
- 17.2 Italy Community Acquired Pneumonia Market Forecast Value (2025-2034)
- 17.3 Italy Community Acquired Pneumonia Market (2018-2034) by Type
- 17.3.1 Market Overview
- 17.3.2 Bacteria
- 17.3.3 Virus
- 17.3.4 Fungi
- 17.4 Italy Community Acquired Pneumonia Market (2018-2034) by Drug Class
- 17.4.1 Market Overview
- 17.4.2 Pleuromutilin Antibiotic
- 17.4.3 Cephalosporin
- 17.4.4 Glycylcycline
- 17.4.5 Oxazolidinone
- 17.4.6 Ketolide
- 17.4.7 Others
- 17.5 Italy Community Acquired Pneumonia Market (2018-2034) by Dosage Form
- 17.5.1 Market Overview
- 17.5.2 Tablet
- 17.5.3 Solution
- 17.5.4 Others
- 17.6 Italy Community Acquired Pneumonia Market (2018-2034) by Route of Administration
- 17.6.1 Market Overview
- 17.6.2 Oral
- 17.6.3 Parenteral
- 17.7 Italy Community Acquired Pneumonia Market (2018-2034) by End User
- 17.7.1 Market Overview
- 17.7.2 Hospitals & Clinics
- 17.7.3 Ambulatory Surgical Centers
- 17.7.4 Homecare Settings
- 17.7.5 Others
- 17.8 Italy Community Acquired Pneumonia Market (2018-2034) by Distribution Channel
- 17.8.1 Market Overview
- 17.8.2 Hospitals Pharmacies
- 17.8.3 Independent Pharmacies
- 17.8.4 Online Pharmacies
- 17.8.5 Others
- 18 Spain Community Acquired Pneumonia Market (2018-2034)
- 18.1 Spain Community Acquired Pneumonia Market Historical Value (2018-2024)
- 18.2 Spain Community Acquired Pneumonia Market Forecast Value (2025-2034)
- 18.3 Spain Community Acquired Pneumonia Market (2018-2034) by Type
- 18.3.1 Market Overview
- 18.3.2 Bacteria
- 18.3.3 Virus
- 18.3.4 Fungi
- 18.4 Spain Community Acquired Pneumonia Market (2018-2034) by Drug Class
- 18.4.1 Market Overview
- 18.4.2 Pleuromutilin Antibiotic
- 18.4.3 Cephalosporin
- 18.4.4 Glycylcycline
- 18.4.5 Oxazolidinone
- 18.4.6 Ketolide
- 18.4.7 Others
- 18.5 Spain Community Acquired Pneumonia Market (2018-2034) by Dosage Form
- 18.5.1 Market Overview
- 18.5.2 Tablet
- 18.5.3 Solution
- 18.5.4 Others
- 18.6 Spain Community Acquired Pneumonia Market (2018-2034) by Route of Administration
- 18.6.1 Market Overview
- 18.6.2 Oral
- 18.6.3 Parenteral
- 18.7 Spain Community Acquired Pneumonia Market (2018-2034) by End User
- 18.7.1 Market Overview
- 18.7.2 Hospitals & Clinics
- 18.7.3 Ambulatory Surgical Centers
- 18.7.4 Homecare Settings
- 18.7.5 Others
- 18.8 Spain Community Acquired Pneumonia Market (2018-2034) by Distribution Channel
- 18.8.1 Market Overview
- 18.8.2 Hospitals Pharmacies
- 18.8.3 Independent Pharmacies
- 18.8.4 Online Pharmacies
- 18.8.5 Others
- 19 Japan Community Acquired Pneumonia Market
- 19.1 Japan Community Acquired Pneumonia Market Historical Value (2018-2024)
- 19.2 Japan Community Acquired Pneumonia Market Forecast Value (2025-2034)
- 19.3 Japan Community Acquired Pneumonia Market (2018-2034) by Type
- 19.3.1 Market Overview
- 19.3.2 Bacteria
- 19.3.3 Virus
- 19.3.4 Fungi
- 19.4 Japan Community Acquired Pneumonia Market (2018-2034) by Drug Class
- 19.4.1 Market Overview
- 19.4.2 Pleuromutilin Antibiotic
- 19.4.3 Cephalosporin
- 19.4.4 Glycylcycline
- 19.4.5 Oxazolidinone
- 19.4.6 Ketolide
- 19.4.7 Others
- 19.5 Japan Community Acquired Pneumonia Market (2018-2034) by Dosage Form
- 19.5.1 Market Overview
- 19.5.2 Tablet
- 19.5.3 Solution
- 19.5.4 Others
- 19.6 Japan Community Acquired Pneumonia Market (2018-2034) by Route of Administration
- 19.6.1 Market Overview
- 19.6.2 Oral
- 19.6.3 Parenteral
- 19.7 Japan Community Acquired Pneumonia Market (2018-2034) by End User
- 19.7.1 Market Overview
- 19.7.2 Hospitals & Clinics
- 19.7.3 Ambulatory Surgical Centers
- 19.7.4 Homecare Settings
- 19.7.5 Others
- 19.8 Japan Community Acquired Pneumonia Market (2018-2034) by Distribution Channel
- 19.8.1 Market Overview
- 19.8.2 Hospitals Pharmacies
- 19.8.3 Independent Pharmacies
- 19.8.4 Online Pharmacies
- 19.8.5 Others
- 20 India Community Acquired Pneumonia Market
- 20.1 India Community Acquired Pneumonia Market (2018-2034) Historical Value (2018-2024)
- 20.2 India Community Acquired Pneumonia Market (2018-2034) Forecast Value (2025-2034)
- 20.3 India Community Acquired Pneumonia Market (2018-2034) by Type
- 20.3.1 Market Overview
- 20.3.2 Bacteria
- 20.3.3 Virus
- 20.3.4 Fungi
- 20.4 India Community Acquired Pneumonia Market (2018-2034) by Drug Class
- 20.4.1 Market Overview
- 20.4.2 Pleuromutilin Antibiotic
- 20.4.3 Cephalosporin
- 20.4.4 Glycylcycline
- 20.4.5 Oxazolidinone
- 20.4.6 Ketolide
- 20.4.7 Others
- 20.5 India Community Acquired Pneumonia Market (2018-2034) by Dosage Form
- 20.5.1 Market Overview
- 20.5.2 Tablet
- 20.5.3 Solution
- 20.5.4 Others
- 20.6 India Community Acquired Pneumonia Market (2018-2034) by Route of Administration
- 20.6.1 Market Overview
- 20.6.2 Oral
- 20.6.3 Parenteral
- 20.7 India Community Acquired Pneumonia Market (2018-2034) by End User
- 20.7.1 Market Overview
- 20.7.2 Hospitals & Clinics
- 20.7.3 Ambulatory Surgical Centers
- 20.7.4 Homecare Settings
- 20.7.5 Others
- 20.8 India Community Acquired Pneumonia Market (2018-2034) by Distribution Channel
- 20.8.1 Market Overview
- 20.8.2 Hospitals Pharmacies
- 20.8.3 Independent Pharmacies
- 20.8.4 Online Pharmacies
- 20.8.5 Others
- 21 Regulatory Framework
- 21.1 Regulatory Overview
- 21.2 US FDA
- 21.3 EU EMA
- 21.4 Japan PMDA
- 21.5 India CDSCO
- 21.6 Others
- 22 Patent Analysis
- 22.1 Analysis by Type of Patent
- 22.2 Analysis by Publication Year
- 22.3 Analysis by Issuing Authority
- 22.4 Analysis by Patent Age
- 22.5 Analysis by CPC Analysis
- 22.6 Analysis by Patent Valuation
- 22.7 Analysis by Key Players
- 23 Clinical Trials and Pipeline Analysis
- 23.1 Analysis by Trial Registration Year
- 23.2 Analysis by Trial Status
- 23.3 Analysis by Trial Phase
- 23.4 Analysis by Therapeutic Area
- 23.5 Analysis by Geography
- 23.6 Drug Pipeline Assessment
- 24 Grants Analysis
- 24.1 Analysis by Year
- 24.2 Analysis by Amount Awarded
- 24.3 Analysis by Issuing Authority
- 24.4 Analysis by Grant Application
- 24.5 Analysis by Funding Institute
- 24.6 Analysis by NIH Departments
- 24.7 Analysis by Recipient Organization
- 25 Funding and Investment Analysis
- 25.1 Analysis by Funding Instances
- 25.2 Analysis by Type of Funding
- 25.3 Analysis by Funding Amount
- 25.4 Analysis by Leading Players
- 25.5 Analysis by Leading Investors
- 25.6 Analysis by Geography
- 26 Strategic Initiatives
- 26.1 Analysis by Partnership Instances
- 26.2 Analysis by Type of Partnership
- 26.3 Analysis by Leading Players
- 26.4 Analysis by Geography
- 27 Supplier Landscape
- 27.1 Market Share by Top 5 Companies
- 27.2 Pfizer, Inc.
- 27.2.1 Financial Analysis
- 27.2.2 Product Portfolio
- 27.2.3 Demographic Reach and Achievements
- 27.2.4 Companies News and Developments
- 27.2.5 Certifications
- 27.3 AstraZeneca
- 27.3.1 Financial Analysis
- 27.3.2 Product Portfolio
- 27.3.3 Demographic Reach and Achievements
- 27.3.4 Companies News and Developments
- 27.3.5 Certifications
- 27.4 Novartis AG
- 27.4.1 Financial Analysis
- 27.4.2 Product Portfolio
- 27.4.3 Demographic Reach and Achievements
- 27.4.4 Companies News and Developments
- 27.4.5 Certifications
- 27.5 Mylan N.V.
- 27.5.1 Financial Analysis
- 27.5.2 Product Portfolio
- 27.5.3 Demographic Reach and Achievements
- 27.5.4 Companies News and Developments
- 27.5.5 Certifications
- 27.6 Sanofi SA
- 27.6.1 Financial Analysis
- 27.6.2 Product Portfolio
- 27.6.3 Demographic Reach and Achievements
- 27.6.4 Companies News and Developments
- 27.6.5 Certifications
- 27.7 Takeda Pharmaceutical Company Limited
- 27.7.1 Financial Analysis
- 27.7.2 Product Portfolio
- 27.7.3 Demographic Reach and Achievements
- 27.7.4 Companies News and Developments
- 27.7.5 Certifications
- 27.8 Sun Pharmaceuticals Inc.
- 27.8.1 Financial Analysis
- 27.8.2 Product Portfolio
- 27.8.3 Demographic Reach and Achievements
- 27.8.4 Companies News and Developments
- 27.8.5 Certifications
- 27.9 AbbVie Inc.
- 27.9.1 Financial Analysis
- 27.9.2 Product Portfolio
- 27.9.3 Demographic Reach and Achievements
- 27.9.4 Companies News and Developments
- 27.9.5 Certifications
- 27.10 GSK plc
- 27.10.1 Financial Analysis
- 27.10.2 Product Portfolio
- 27.10.3 Demographic Reach and Achievements
- 27.10.4 Companies News and Developments
- 27.10.5 Certifications
- 28 Key Opinion Leaders (KOL) Insights (Additional Insight)
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
- **The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.